Charles Schwab Investment Management Inc. Buys 2,301 Shares of Grifols, S.A. (NASDAQ:GRFS)

Charles Schwab Investment Management Inc. boosted its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 7.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,543 shares of the biotechnology company’s stock after acquiring an additional 2,301 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Grifols were worth $280,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Hantz Financial Services Inc. purchased a new stake in shares of Grifols in the second quarter worth $1,235,000. Natixis Advisors LLC increased its stake in Grifols by 116.0% in the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock worth $971,000 after buying an additional 82,723 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Grifols by 56.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 55,887 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 20,120 shares during the period. Black Creek Investment Management Inc. lifted its position in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after acquiring an additional 881,155 shares in the last quarter. Finally, Highland Peak Capital LLC bought a new position in shares of Grifols in the second quarter worth about $5,991,000.

Grifols Trading Up 3.9 %

Grifols stock opened at $7.72 on Friday. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The firm’s 50 day moving average price is $8.37 and its 200-day moving average price is $8.10. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The stock has a market cap of $5.31 billion, a P/E ratio of 7.96 and a beta of 0.43.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.